Literature DB >> 15763953

Antioxidant activity and neuroprotective effects of zolpidem and several synthesis intermediates.

Guillermo García-Santos1, Federico Herrera, Vanesa Martín, Jezabel Rodriguez-Blanco, Isaac Antolín, Felix Fernández-Marí, Carmen Rodriguez.   

Abstract

Structural relationship between the antioxidant melatonin and the non-benzodiazepine hypnotic zolpidem (ZPD) suggests possible direct antioxidant and neuroprotective properties of this compound. In the present work, these effects were analyzed for zolpidem and four of its synthesis intermediates. In vitro assays include lipid peroxidation and protein oxidation studies in liver and brain homogenates. Intracellular antioxidant effects were analyzed by evaluation of free radical formation prevention in HT-22 hippocampal cells treated with glutamate 10mM and measured by flow cytometer DCF fluorescence. The neuroprotective effect of these compounds was evaluated as neuronal death prevention of HT-22 cells treated with the same concentration of glutamate. Zolpidem was found to prevent induced lipid peroxidation in rat liver and brain homogenates showing figures similar to melatonin, although it failed to prevent protein oxidation. ZPD-I was the most effective out of the several zolpidem intermediates studied as it prevented lipid peroxidation with an efficiency higher than melatonin or zolpidem and with an effectiveness similar to estradiol and trolox. ZPD-I prevents protein oxidation, which trolox is known to be unable to prevent. When cellular experiments were undertaken, ZPD-I prevented totally the increase of intracellular free radicals induced by glutamate 10mM in culture medium for 12h, while zolpidem and ZPD-III partially prevented this increase. Also the three compounds protected hippocampal neurons from glutamate-induced death in the same conditions, being their comparative efficacy, ZPD-III > ZPD-I = ZPD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15763953     DOI: 10.1080/10715760400017343

Source DB:  PubMed          Journal:  Free Radic Res        ISSN: 1029-2470


  6 in total

1.  Emulated Clinical Trials from Longitudinal Real-World Data Efficiently Identify Candidates for Neurological Disease Modification: Examples from Parkinson's Disease.

Authors:  Daphna Laifenfeld; Chen Yanover; Michal Ozery-Flato; Oded Shaham; Michal Rosen-Zvi; Nirit Lev; Yaara Goldschmidt; Iris Grossman
Journal:  Front Pharmacol       Date:  2021-04-22       Impact factor: 5.810

Review 2.  Iron, oxidative stress and gestational diabetes.

Authors:  Taifeng Zhuang; Huijun Han; Zhenyu Yang
Journal:  Nutrients       Date:  2014-09-25       Impact factor: 5.717

3.  Effect of zolpidem on functional recovery in a rat model of ischemic stroke.

Authors:  Min-Kyun Oh; Kyung Jae Yoon; Yong-Taek Lee; Seoung Wan Chae; Hye Young Choi; Hee Suk Shin; Yun Hee Park; Se-Woong Chun; Young Sook Park
Journal:  J Int Med Res       Date:  2017-08-23       Impact factor: 1.671

4.  ROS-Induced GATA4 and GATA6 Downregulation Inhibits StAR Expression in LPS-Treated Porcine Granulosa-Lutein Cells.

Authors:  Xiaolu Qu; Leyan Yan; Rihong Guo; Hui Li; Zhendan Shi
Journal:  Oxid Med Cell Longev       Date:  2019-04-22       Impact factor: 6.543

5.  The antioxidant and neuroprotective effects of Zolpidem on acrylamide-induced neurotoxicity using Wistar rat primary neuronal cortical culture.

Authors:  Bahareh Sadat Yousefsani; Nasim Akbarizadeh; Jalal Pourahmad
Journal:  Toxicol Rep       Date:  2020-01-27

Review 6.  Can a Positive Allosteric Modulation of GABAergic Receptors Improve Motor Symptoms in Patients with Parkinson's Disease? The Potential Role of Zolpidem in the Treatment of Parkinson's Disease.

Authors:  Antonio Daniele; Francesco Panza; Antonio Greco; Giancarlo Logroscino; Davide Seripa
Journal:  Parkinsons Dis       Date:  2016-05-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.